Peripheral delivery of recombinant irisin protein via intraperitoneal injection was sufficient to reduce levels of pro-neuroinflammatory markers GFAP, interleukin-1β (IL-1β) and interleukin-6 (IL-6) in the CNS of a streptozotocin-induced diabetic mouse model (52). This evidence concerns the gene IL6 and diabetes mellitus.